Search
for
Sort by
Research 541–570 of 543
- Epigenetic age estimation in saliva and in buccal cells
- Data-driven strategies for drug repurposing: insights, recommendations, and case studies
- Heavy metals in biological samples of cancer patients: a systematic literature review
- PD59-09 PHOSPHODIESTERASE INHIBITORS COULD REVERSE THE PROLIFERATION OF BPH EPITHELIAL CELLS INDUCED BY CD8+ T CELLS IN LOW ANDROGEN CONDITION
- Phosphodiesterase (PDE) Inhibitors for the Treatment of Inflammatory Skin Conditions
- Systematic review of newer agents for the management of alopecia areata in adults: Janus kinase inhibitors, biologics and phosphodiesterase‐4 inhibitors
- The effect of cilostazol, a phosphodiesterase 3 (PDE3) inhibitor, on human hair growth with the dual promoting mechanisms
- Efficacy of the phosphodiesterase-4 inhibitor, apremilast, in a patient with severe alopecia areata
- The effects of phosphodiesterase 3 (PDE3) inhibitor on hair follicle cell viability and hair growth
- Phosphodiesterase inhibitors and prostaglandin analogues in dermatology: A comprehensive review
- The use of phosphodiesterase inhibitors for the treatment of alopecia
- Comment on ‘Androgenetic alopecia is associated with increased scalp hardness’: role of phosphodiesterase inhibitors?
- 467 Novel selective phosphodiesterase inhibitors promote the adipogenic function of dermal fibroblasts: Implication to treat hair loss
- Phosphodiesterase inhibitors used in androgenic alopecia as a possible risk factor for testicular tumor
- Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
- Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
- Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
- 5-Alpha-Reductase Inhibitors and Combination Therapy
- FDA approves label addition for PDE-5 inhibitor
- 570 Targeting phosphodiesterase 8A (PDE8A) to boost adipogenesis and hair regeneration
- Sexual Dysfunction Related to Drugs: a Critical Review. Part V: α-Blocker and 5-ARI Drugs
- Drug repurposing of cyclin-dependent kinase inhibitors for neutrophilic acute respiratory distress syndrome and psoriasis
- Investigation, treatment and monitoring of late‐onset hypogonadism in males: ISA, ISSAM, and EAU recommendations
- Efficacy and Side Effects of Drugs Commonly Used for the Treatment of Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia
- Risks and side effects in the medical management of benign prostatic hyperplasia
- Pharmacological Approaches in Managing Symptomatic Relief of Benign Prostatic Hyperplasia: A Comprehensive Review
- Wider clinical applications of fumaric acid esters: A useful option in psoriasis patients with multiple sclerosis
- Medical management of benign prostatic hyperplasia
- Platelet-Rich Plasma for Urologic Conditions: An Early Call for Composition Reporting
- Most recent findings of curative drugs for lower urinary tract symptoms in clinical practice